Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Secobarbital. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.65 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.65 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.65 |
| ▸ | MMP9 | P14780 | 1/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.65 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Secobarbital SCHEMBL41182 | 1.00 | MMP9 (0.97) | MMP9CYP3A4KDM4EALDH1A1GABRB3 | |
| Secobarbital SCHEMBL7599361 | 1.00 | MMP9 (0.97) | MMP9CYP3A4KDM4EALDH1A1GABRB3 | |
| Secobarbital SCHEMBL80734 | 0.98 | MMP9 (1.00) | MMP9CYP3A4KDM4EALDH1A1GABRB3 | |
| Secobarbital SCHEMBL41181 | 0.98 | MMP9 (1.00) | MMP9CYP3A4KDM4EALDH1A1GABRB3 | |
| Secobarbital SCHEMBL80735 | 0.98 | MMP9 (1.00) | MMP9CYP3A4KDM4EALDH1A1GABRB3 | |
| Secobarbital SCHEMBL8085730 | 0.98 | MMP9 (1.00) | MMP9CYP3A4KDM4EALDH1A1GABRB3 | |
| Secobarbital SCHEMBL28198576 | 0.95 | MMP9 (0.94) | MMP9CYP3A4KDM4EALDH1A1GABRB3 | |
| Secobarbital SCHEMBL7778384 | 0.90 | MMP9 (0.83) | MMP9CYP3A4KDM4EALDH1A1GABRB3 | |
| Thiamylal SCHEMBL34747 | 0.89 | MMP9 (0.77) | MMP9CYP3A4KDM4EALDH1A1GABRB3 | |
| Thiamylal SCHEMBL548050 | 0.87 | MMP9 (0.79) | MMP9CYP3A4KDM4EALDH1A1GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116179496-A | Hybridoma cell strain secreting anti-phenobarbital drug monoclonal multi-residue antibody and application thereof | 江南大学 | 2023-05-30 | — | — | CN | claimed |
| EP-2748000-B1 | KIT COMPRISING A PACKAGING MATERIAL AND A SOLID PHARMACEUTICAL OR NUTRACEUTICAL PRODUCT CONTAINED IN THE PACKAGING MATERIAL | SIEGFRIED LTD (CH) | 2020-11-18 | — | — | EP | claimed |
| US-9414988-B2 | Kit comprising a packaging material and a solid pharmaceutical or nutraceutical product contained in the packaging material | SIEGFRIED LTD. (CH) | 2016-08-16 | — | — | US | claimed |
| US-20140190866-A1 | KIT COMPRISING A PACKAGING MATERIAL AND A SOLID PHARMACEUTICAL OR NUTRACEUTICAL PRODUCT CONTAINED IN THE PACKAGING MATERIAL | SIEGFRIED LTD. (CH) | 2014-07-10 | — | — | US | claimed |
| EP-2748000-A1 | KIT COMPRISING A PACKAGING MATERIAL AND A SOLID PHARMACEUTICAL OR NUTRACEUTICAL PRODUCT CONTAINED IN THE PACKAGING MATERIAL | Siegfried Ltd. (CH) | 2014-07-02 | — | — | EP | claimed |
| WO-2013034273-A1 | KIT COMPRISING A PACKAGING MATERIAL AND A SOLID PHARMACEUTICAL OR NUTRACEUTICAL PRODUCT CONTAINED IN THE PACKAGING MATERIAL | SIEGFRIED LTD. (CH) | 2013-03-14 | — | — | WO | claimed |
| EP-1317304-B1 | SLOW RELEASE PHARMACEUTICAL PREPARATION AND METHOD OF ADMINISTERING SAME | PALMAYA PTY LTD (AU) | 2011-04-27 | — | — | EP | claimed |
| US-6309669-B1 | Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2001-10-30 | — | — | US | claimed |
| US-3989823-A | COMBATING SMOKING | COSTANZO FRANCOIS DI | 1976-11-02 | — | — | US | claimed |
| EP-4682141-A1 | TRICYCLIC COMPOUND | ONO Pharmaceutical Co., Ltd. (JP) | 2026-01-21 | — | — | EP | disclosed |
| EP-4584371-A2 | REPROGRAMMING TROPISM VIA DISPLAYED PEPTIDES TILING RECEPTOR-LIGANDS | The Regents of the University of California (US) | 2025-07-16 | — | — | EP | disclosed |
| CN-119855901-A | Tiling receptor-ligand reprogramming chemotaxis via display peptides | 加利福尼亚大学董事会 | 2025-04-18 | — | — | CN | disclosed |
| US-20250057823-A1 | COMPOSITION FOR IMPROVING CARDIAC FUNCTION | KYOTO UNIVERSITY (JP) | 2025-02-20 | — | — | US | disclosed |
| CN-119233828-A | Nano encapsulated pharmaceutical composition and use thereof | 福君基因公司 | 2024-12-31 | — | — | CN | disclosed |
| US-3989823-A | COMBATING SMOKING | COSTANZO FRANCOIS DI | 1976-11-02 | — | — | US | disclosed |
| US-3975237-A | LIGANDS | SYVA COMPANY (US) | 1976-08-17 | — | — | US | disclosed |
| US-3966556-A | Compounds for enzyme amplification assay methadone analogs | SYVA COMPANY (US) | 1976-06-29 | — | — | US | disclosed |
| US-3966764-A | ELECTRON SPIN RESONANCE | SYVA COMPANY (US) | 1976-06-29 | — | — | US | disclosed |
| US-3966744-A | Spin labeled compounds | SYVA COMPANY (US) | 1976-06-29 | — | — | US | disclosed |
| US-3954793-A | INSECTICIDES | HENNESSY DOUGLAS J | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250057823-A1 | COMPOSITION FOR IMPROVING CARDIAC FUNCTION | TNNI3, NPPA, TNNT2 | GABRB3 2945/4885GABRA2 3925/4885GABRB2 3251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.